Quantum Surgical, based in Montpellier, France, designs medical robots specialized in minimally invasive cancer treatment, including Epione, developed for liver cancer. The startup announced that it has raised €40 million to develop this robot

Founded in 2017 by Bertin Nahum, CEO, Fernand Badano, Managing Director and Lucien Blondel, CTO, Quantum Surgical is growing significantly in the medical robotics sector. The €40 million fundraising was led by Ally Bridge Group (ABG), a global life sciences investment group, with a €20 million contribution. The European Investment Bank, Bpi France and the Caisse d’Epargne Languedoc Roussillon also participated in this latest investment. The total amount of funds raised by Quantum Surgical since its creation is therefore 50 million.

“We are delighted to have closed this round of funding and honored by the continued strong support of our historical investor, Ally Bridge Group, and this since our previous company Medtech SA, prior to its acquisition by Zimmer Biomet in 2016. This additional funding will help us accelerate the clinical adoption of Epione® our medical robot for the treatment of liver cancer,” said Bertin Nahum, President and Co-Founder of Quantum Surgical.

Quantum Surgical has obtained CE Mark approval for Epione after successfully treating 21 patients with the robot. This approval allows the commercialization of Epione. It will assist physicians in safer and more effective percutaneous tumor removal from the abdomen. The technique involves inserting a needle through the skin to destroy tumors. Epione will allow more patients to benefit from minimally invasive treatments, especially since imaging allows cancers to be detected at an early stage.

“As an early investor in Quantum Surgical, ABG is proud to continue to support the company’s remarkable achievements during Covid-19, as evidenced by its recent CE Mark achievement,” said Frank Yu, Founder, CEO of Ally Bridge Group. “We expect Quantum Surgical to achieve significant development milestones in the near term that will enable Epione® to treat more liver cancer patients more quickly and effectively than the care currently offered.”

Ambroise Fayolle, Vice-President of the European Investment Bank, also recalled the importance of innovation in the health sector:

“The EIB is pleased to contribute to the development of Quantum Surgical and its innovative technology to improve the treatment of liver cancer. In the face of the continuing challenges posed by Covid-19, this EUR 15 million financing, with the support of the Pan-European Guarantee Fund (EGF), demonstrates the importance that Europe places on supporting innovation and promising technologies in healthcare, a sector that is essential for the well-being of people.”

Translated from La startup montpelliéraine Quantum Surgical spécialisée en robotique médicale lève 40 millions d’euros